The Expression of Thymidylate Synthase in Breast Cancer / 한국유방암학회지
Journal of Korean Breast Cancer Society
;
: 227-239, 1999.
Artigo
em Coreano
| WPRIM
| ID: wpr-76261
ABSTRACT
Fluorouracil is well known as a standard chemotherapeutic drug in breast cancer and other cancers that is converted to flurodeoxyuridine monophosphate (FdUMP) and leads to the inhibition of thymidylate synthase (TS) in tumor tissue. The role of this enzyme is the catalysis of the methylation from deoxyuridine monophosphate (dUMP) to deozythymidine monophosphate (dUMP), which is a very important process for DNA synthesis in tumor tissues. Increased level of TS protein correlates inversely with sensitivity and response to 5 FU in human cancer cell lines. Authurs evaluated the TS expression level using the immunohistochmical staining and analysed their relationship with other prognostic factors and clinical outcome of breast cancer patients. The results were as follows; 1) TS level was not related histopathologic stage, involvement of axillary lymph nodes, estrogen receptor, progesterone receptor, recurrent type, primary tmor and recurrent tumors, disease free survival rate. 2) TS level was associated with e-erbB2 overexpression. 3) c-erbB2 overexpression was related with recurrence rate. 4) TS level appeared to be related with recurrence rate. So w conclude the TS level can be used as an independant prognostic predictor on breast cancer patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Recidiva
/
Timidilato Sintase
/
Mama
/
Neoplasias da Mama
/
DNA
/
Catálise
/
Receptores de Progesterona
/
Linhagem Celular
/
Intervalo Livre de Doença
/
Desoxiuridina
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Breast Cancer Society
Ano de publicação:
1999
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS